Skip to main content

Supporting in vivo CAR development for blood cancers

Abintus

Abintus Bio

INC

Abintus Bio

Project Term: November 3, 2020 - TBD

In November 2020, LLS made an equity investment in Abintus Bio to "Support in vivo CAR Development for Blood Cancers." Abintus plans to develop a portfolio of first-in-class product candidates that reprogram immune cells in vivo to eliminate tumors utilizing proprietary vectors and vector-engineering technologies to develop an in vivo chimeric antigen receptor (CAR) T platform based on a non-replicating gammaretrovirus. This technology is currently in preclinical testing and could, if successful, support immediate patient dosing, a substantial benefit for patients facing advanced forms of cancer with a poor prognosis. Abintus’ platform is versatile and scalable, so they have the potential to meet the needs of a much larger patient population.

Lay Abstract

For additional information, please visit https://lls.org/therapy-acceleration-program-portfolio

Program
Therapy Acceleration Program
To All Projects